Recruiting studies: Malignant Peripheral Nerve Sheath Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831 A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06041516 Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Phase N/A · 13 location(s) · Washington University School of Medicine · NCT03141021 IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Phase 2 · 1 location(s) · Fudan University · NCT06849986 DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Asses
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT07298083 Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT04222413 A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Maligna
EARLY_Phase 1 · 1 location(s) · University of Minnesota · NCT06693284 Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase 1 · 25 location(s) · Bristol-Myers Squibb · NCT05245500 NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · 7 location(s) · St. Jude Children's Research Hospital · NCT06239272 A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04872543 SPEARHEAD-3 Pediatric Study
Phase 1/Phase 2 · 10 location(s) · USWM CT, LLC · NCT05642455 Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgi
EARLY_Phase 1 · 1 location(s) · Eben Rosenthal · NCT07493447 Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Phase 1/Phase 2 · 2 location(s) · AeRang Kim · NCT06735820 Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931 A Study of DEG6498 in Participants With Solid Tumors
Phase 1 · 3 location(s) · Degron Therapeutics Co. · NCT07244835 Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06222203 A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Phase 2 · 16 location(s) · Memorial Sloan Kettering Cancer Center · NCT05985161 B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT04897321 Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonan
NA · 1 location(s) · Nicole Baca · NCT04763109 MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Phase 2 · 1 location(s) · HRYZ Biotech Co. · NCT06277154 Neurofibromatosis Type 1 Tumor Early Detection Study
Phase N/A · 1 location(s) · David Miller · NCT06515860

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.